Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Merck & Co. Hold Rating: Balancing Promising Trial Results With Market Dynamics and Future Uncertainties
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $136
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating
Jefferies Adjusts Price Target on Merck to $149 From $148, Maintains Buy Rating
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $149
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $145
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $148
Jefferies Adjusts Price Target on Merck to $148 From $147, Maintains Buy Rating
Merck Initiated at Peer Perform by Wolfe Research
Merck & Co Analyst Ratings
Wolfe Research Downgrades Merck & Co(MRK.US) to Hold Rating
Argus Cuts Price Target on Merck to $125 From $140
Daiwa Downgrades Merck & Co(MRK.US) to Hold Rating
Daiwa Securities Downgrades Merck to Neutral From Outperform, Adjusts Price Target to $100 From $130
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $130
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $130
Merck Is Maintained at Buy by Truist Securities